ZEB1 and breast carcinoma: Given our observation that USP51 directly binds and deubiquitinates ZEB1, it follows that disrupting the interaction between USP51 and ZEB1 would severely diminish ZEB1 activity and thus the aggressiveness of breast cancer in vitro and in vivo.